Vicore Pharma Holding AB Cash Flow Statement

Financials in millions SEK. Fiscal year is January - December.

Millions SEK. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	2020 - 2016
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	2020 - 2016
Net Income	-477.47	-168.63	-310.94	-288.42	-296.48	Upgrade
Depreciation & Amortization	-	2.24	3.42	3.61	3.6	Upgrade
Loss (Gain) From Sale of Assets	-	-	-	2	-	Upgrade
Asset Writedown & Restructuring Costs	-	-	62.55	-	-	Upgrade
Other Operating Activities	61.01	3.28	6.03	3.83	0.64	Upgrade
Change in Accounts Receivable	-2.86	-35.6	-4.28	-1.6	-0.34	Upgrade
Change in Accounts Payable	44.89	33.77	-6.36	-19.34	27.41	Upgrade
Operating Cash Flow	-374.44	-164.95	-249.58	-299.92	-265.17	Upgrade
Sale (Purchase) of Intangibles	-	-	-	-3	-	Upgrade
Investment in Securities	-599.32	149.04	-144.46	77	-7	Upgrade
Other Investing Activities	-2.49	-	-	-	-	Upgrade
Investing Cash Flow	-601.81	149.04	-144.46	74	-7	Upgrade
Issuance of Common Stock	455.1	882.14	500.41	200	336	Upgrade
Other Financing Activities	-24.55	-48.08	-29.55	-12.96	-17.82	Upgrade
Financing Cash Flow	430.54	834.06	470.86	187.04	318.18	Upgrade
Foreign Exchange Rate Adjustments	-32.16	4.23	-	1.48	-0.43	Upgrade
Net Cash Flow	-577.85	822.38	76.82	-37.4	45.58	Upgrade
Free Cash Flow	-374.44	-164.95	-249.58	-299.92	-265.17	Upgrade
Free Cash Flow Margin	-9809.67%	-150.85%	-	-	-	Upgrade
Free Cash Flow Per Share	-1.56	-1.21	-2.58	-4.15	-3.81	Upgrade
Cash Interest Paid	0.06	0.01	0	0.01	0.01	Upgrade
Levered Free Cash Flow	-253.22	-111.57	-200.41	-195.17	-160.92	Upgrade
Unlevered Free Cash Flow	-221.75	-111.56	-200.41	-195.16	-160.92	Upgrade
Change in Working Capital	42.03	-1.84	-10.65	-20.94	27.07	Upgrade

Source: S&P Capital IQ. Standard template. Financial Sources.